RU2018119359A - Способ индукции пролиферации кардиомиоцитов и лечения заболеваний сердца - Google Patents
Способ индукции пролиферации кардиомиоцитов и лечения заболеваний сердца Download PDFInfo
- Publication number
- RU2018119359A RU2018119359A RU2018119359A RU2018119359A RU2018119359A RU 2018119359 A RU2018119359 A RU 2018119359A RU 2018119359 A RU2018119359 A RU 2018119359A RU 2018119359 A RU2018119359 A RU 2018119359A RU 2018119359 A RU2018119359 A RU 2018119359A
- Authority
- RU
- Russia
- Prior art keywords
- agrin
- agrin peptide
- domain
- induces
- peptide
- Prior art date
Links
- 208000019622 heart disease Diseases 0.000 title claims 4
- 230000035755 proliferation Effects 0.000 title claims 4
- 230000001939 inductive effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 101150079978 AGRN gene Proteins 0.000 claims 13
- 108700019743 Agrin Proteins 0.000 claims 13
- 102100040026 Agrin Human genes 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 210000004413 cardiac myocyte Anatomy 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101000959594 Homo sapiens Agrin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
Claims (10)
1. Применение терапевтически эффективного количества агринового пептида, который индуцирует пролиферацию кардиомиоцитов, в изготовлении лекарственного препарата для лечения заболевания сердца, причем указанный агриновый пептид не является частью слитого полипептида, и причем указанный агриновый пептид содержит ламинин-G-подобный домен 1 (G1) и ламинин-G-подобный домен 2 (G2).
2. Применение средства, которое ингибирует дистрогликановый комплекс на кардиомиоцитах, в изготовлении лекарственного препарата для лечения заболевания сердца, причем указанное средство содержит агриновый пептид, который индуцирует пролиферацию кардиомиоцитов, указанный агриновый пептид не является частью слитого полипептида, и причем указанный агриновый пептид содержит ламинин-G-подобный домен 1 (G1) и ламинин-G-подобный домен 2 (G2).
3. Применение по п. 2, причем указанное средство содержит указанный агриновый пептид, который индуцирует иммуномодуляцию.
4. Применение по любому из пп. 2-3, причем указанное средство индуцирует активацию Erk.
5. Применение по любому из пп. 2-4, причем указанное средство ингибирует саркомерогенез.
6. Имплантируемое устройство, содержащее агриновый пептид, который индуцирует пролиферацию кардиомиоцитов, причем указанный агриновый пептид не является частью слитого полипептида, и причем указанный агриновый пептид содержит ламинин-G-подобный домен 1 (G1) и ламинин-G-подобный домен 2 (G2).
7. Устройство по п. 6, причем указанный агриновый пептид индуцирует иммуномодуляцию.
8. Применение по любому из пп. 1-5, причем указанный агриновый пептид имеет растворимую форму.
9. Применение по любому из пп. 1-5 и 8, причем указанный агриновый пептид содержит фрагмент агрина человека.
10. Применение по любому из пп. 1-5 и 8-9, причем указанное заболевание сердца является ишемической болезнью сердца.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL242380 | 2015-10-29 | ||
| IL242380A IL242380A0 (en) | 2015-10-29 | 2015-10-29 | A method for inducing the division of cardiomyocytes and treating heart diseases |
| PCT/IL2016/051165 WO2017072772A1 (en) | 2015-10-29 | 2016-10-27 | A method of inducing cardiomyocytes proliferation and treating heart diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018119359A true RU2018119359A (ru) | 2019-11-29 |
| RU2018119359A3 RU2018119359A3 (ru) | 2020-02-13 |
Family
ID=57286770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119359A RU2018119359A (ru) | 2015-10-29 | 2016-10-27 | Способ индукции пролиферации кардиомиоцитов и лечения заболеваний сердца |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10589132B2 (ru) |
| EP (2) | EP3368058B1 (ru) |
| CN (1) | CN108495647B (ru) |
| AU (2) | AU2016347661B2 (ru) |
| DK (1) | DK3368058T5 (ru) |
| ES (1) | ES2949348T3 (ru) |
| IL (1) | IL242380A0 (ru) |
| RU (1) | RU2018119359A (ru) |
| WO (1) | WO2017072772A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method for inducing the division of cardiomyocytes and treating heart diseases |
| EP3634495A4 (en) * | 2017-06-01 | 2021-02-24 | Baylor College of Medicine | Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation |
| EP3716993A1 (en) | 2017-12-03 | 2020-10-07 | Yeda Research and Development Co. Ltd | Treatment of an ischemic heart disease |
| US12162994B2 (en) | 2018-03-02 | 2024-12-10 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
| TW202014181A (zh) | 2018-04-04 | 2020-04-16 | 美商希吉隆醫療公司 | 可植入顆粒及相關方法 |
| CN109734790B (zh) * | 2019-01-17 | 2022-05-24 | 武汉明德生物科技股份有限公司 | 人Agrin抗原、人Agrin抗体检测试剂盒及其制备方法与应用 |
| BR112021019139A2 (pt) * | 2019-03-27 | 2021-11-30 | Sigilon Therapeutics Inc | Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry |
| IL292957A (en) | 2022-05-11 | 2023-12-01 | Yeda res & development co ltd | Treatment of heart disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5814478A (en) | 1995-12-15 | 1998-09-29 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
| US6413740B1 (en) | 1995-12-15 | 2002-07-02 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| AP2764A (en) | 2005-01-31 | 2013-09-30 | Mylan Lab Inc | Hydroxylated nebivolol metabolites |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| US20070014869A1 (en) | 2005-07-15 | 2007-01-18 | Cormatrix Cardiovascular, Inc. | Compositions for reconstruction, replacement or repair of intracardiac tissue |
| US8568761B2 (en) | 2005-07-15 | 2013-10-29 | Cormatrix Cardiovascular, Inc. | Compositions for regenerating defective or absent myocardium |
| WO2007011682A2 (en) * | 2005-07-15 | 2007-01-25 | Regents Of The University Of California | Methods and reagents for screening new drugs and for treating ion pump associated disorders and diseases |
| WO2008021896A2 (en) | 2006-08-08 | 2008-02-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic methods for neuropathic pain |
| US8632764B2 (en) | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| EP2295068A1 (en) | 2009-09-04 | 2011-03-16 | Neurotune AG | Modified agrin-fragment capable of restoring muscle strength for use as a medicament |
| TWI480070B (zh) | 2011-04-21 | 2015-04-11 | Univ Kaohsiung Medical | 具礦質親和能力之多歧狀胜肽構型 |
| IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method for inducing the division of cardiomyocytes and treating heart diseases |
| EP3716993A1 (en) | 2017-12-03 | 2020-10-07 | Yeda Research and Development Co. Ltd | Treatment of an ischemic heart disease |
-
2015
- 2015-10-29 IL IL242380A patent/IL242380A0/en unknown
-
2016
- 2016-10-27 CN CN201680077347.3A patent/CN108495647B/zh active Active
- 2016-10-27 WO PCT/IL2016/051165 patent/WO2017072772A1/en not_active Ceased
- 2016-10-27 AU AU2016347661A patent/AU2016347661B2/en active Active
- 2016-10-27 ES ES16794758T patent/ES2949348T3/es active Active
- 2016-10-27 DK DK16794758.9T patent/DK3368058T5/da active
- 2016-10-27 US US15/772,065 patent/US10589132B2/en active Active
- 2016-10-27 EP EP16794758.9A patent/EP3368058B1/en active Active
- 2016-10-27 RU RU2018119359A patent/RU2018119359A/ru not_active Application Discontinuation
- 2016-10-27 EP EP23171073.2A patent/EP4400164A3/en active Pending
-
2020
- 2020-01-19 US US16/746,878 patent/US11786640B2/en active Active
-
2023
- 2023-07-27 AU AU2023208156A patent/AU2023208156A1/en active Pending
- 2023-09-14 US US18/368,332 patent/US20240042104A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180318612A1 (en) | 2018-11-08 |
| US11786640B2 (en) | 2023-10-17 |
| DK3368058T3 (da) | 2023-07-24 |
| ES2949348T3 (es) | 2023-09-27 |
| DK3368058T5 (da) | 2024-09-30 |
| AU2016347661A1 (en) | 2018-06-14 |
| EP3368058A1 (en) | 2018-09-05 |
| US10589132B2 (en) | 2020-03-17 |
| US20240042104A1 (en) | 2024-02-08 |
| EP4400164A2 (en) | 2024-07-17 |
| AU2023208156A1 (en) | 2023-08-17 |
| CN108495647B (zh) | 2022-04-12 |
| RU2018119359A3 (ru) | 2020-02-13 |
| EP3368058B1 (en) | 2023-05-03 |
| IL242380A0 (en) | 2016-02-01 |
| EP4400164A3 (en) | 2024-09-11 |
| AU2016347661B2 (en) | 2023-08-17 |
| CN108495647A (zh) | 2018-09-04 |
| US20200139162A1 (en) | 2020-05-07 |
| WO2017072772A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018119359A (ru) | Способ индукции пролиферации кардиомиоцитов и лечения заболеваний сердца | |
| IL280483A (en) | Muscle targeting complexes and uses thereof for treating pompe disease | |
| MX2024010140A (es) | Nuevos metodos. | |
| EP3880823A4 (en) | Therapeutic adeno-associated virus for treating pompe disease | |
| IL285270A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL285269A (en) | Compositions and methods for treating neurocognitive disorders | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| HUE059050T2 (hu) | Aminosavakat tartalmazó készítmények mitokondriális rendellenességgel összefüggõ betegségek kezelésében történõ alkalmazásra | |
| PL3377637T3 (pl) | Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EP3003343A4 (en) | BIOMIMETIC PEPTIDE AND BIODEGRADABLE OUTPUT PLATFORM FOR THE TREATMENT OF ANGIOGENESIS AND LYMPHANGIOGENESIS DEPENDENT ILLNESSES | |
| HUE060322T2 (hu) | Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| EP3643723C0 (en) | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES COMPRISING SAID NOVEL PEPTIDE AS ACTIVE INGREDIENT | |
| EP3290514C0 (en) | APPLICATION OF PI4KIII.ALPHA PROTEIN AND ASSOCIATED MEMBRANE PROTEIN COMPLEX IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| EP3685840A4 (en) | PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES | |
| MX378431B (es) | Uso terapèutico de proteìnas morfogenèticas òseas. | |
| SG11202006494VA (en) | Therapeutic peptides and methods for treating autoimmune related disease | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| IL285452A (en) | New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine | |
| WO2017143115A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| BR112018015826A2 (pt) | anticorpos monoclonais específicos egfl6 e métodos de seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200806 |